7.52
-0.16 (-2.08%)
| Previous Close | 7.68 |
| Open | 7.58 |
| Volume | 1,036,869 |
| Avg. Volume (3M) | 3,275,412 |
| Market Cap | 511,779,808 |
| Price / Earnings (Forward) | 3.64 |
| Price / Book | 8.44 |
| 52 Weeks Range | |
| Earnings Date | 12 Nov 2025 |
| Diluted EPS (TTM) | -3.04 |
| Current Ratio (MRQ) | 1.16 |
| Operating Cash Flow (TTM) | -142.86 M |
| Levered Free Cash Flow (TTM) | -102.50 M |
| Return on Assets (TTM) | -30.70% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Omeros Corporation | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 1.50 |
|
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 4.40% |
| % Held by Institutions | 47.30% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 45.00 (WBB Securities, 498.40%) | Buy |
| Median | 36.00 (378.72%) | |
| Low | 20.00 (HC Wainwright & Co., 165.96%) | Buy |
| Average | 33.67 (347.74%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 10.22 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| D. Boral Capital | 16 Oct 2025 | 36.00 (378.72%) | Buy | 9.83 |
| 15 Oct 2025 | 36.00 (378.72%) | Buy | 10.42 | |
| HC Wainwright & Co. | 15 Oct 2025 | 20.00 (165.96%) | Buy | 10.42 |
| WBB Securities | 15 Oct 2025 | 45.00 (498.40%) | Buy | 10.42 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 16 Oct 2025 | Announcement | Omeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients Treated with Narsoplimab Versus a Well-Matched External Control Group |
| 02 Sep 2025 | Announcement | Omeros Announces Publication Highlighting Survival Outcomes in TA-TMA Patients Treated with Narsoplimab Under Its Global Expanded Access Program |
| 14 Aug 2025 | Announcement | Omeros Corporation Reports Second Quarter 2025 Financial Results |
| 11 Aug 2025 | Announcement | Omeros Corporation to Announce Second Quarter Financial Results on August 14, 2025 |
| 31 Jul 2025 | Announcement | D. Boral Capital Acted as Exclusive Placement Agent to Omeros Corporation (Nasdaq: OMER) in Connection with its $22,000,000 Registered Direct Offering |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |